These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2940581)

  • 41. First report of the use of meglumine antimoniate for treatment of canine leishmaniasis in a pregnant dog.
    Spada E; Proverbio D; Groppetti D; Perego R; Grieco V; Ferro E
    J Am Anim Hosp Assoc; 2011; 47(1):67-71. PubMed ID: 21164165
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antimony containing drug and ECG abnormalities in children with visceral leishmaniasis.
    Zanoni LZ; Brustoloni YM; Melnikov P; Cônsolo CE
    Biol Trace Elem Res; 2009 Dec; 132(1-3):35-40. PubMed ID: 19424667
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog.
    Chapman WL; Hanson WL; Alving CR; Hendricks LD
    Am J Vet Res; 1984 May; 45(5):1028-30. PubMed ID: 6732008
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Kala-azar in childhood. 20 year review].
    Cambronero Galache M; Martínez Cortés F; Bódalo Herrero A; Courel Grijalba A; Casado Flores J; Casquero Junquera J
    An Esp Pediatr; 1983 Jan; 18(1):28-32. PubMed ID: 6870075
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Visceral childhood leishmaniasis in southern Turkey: experience of twenty years.
    Dursun O; Erişir S; Yeşilipek A
    Turk J Pediatr; 2009; 51(1):1-5. PubMed ID: 19378883
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [A case of antimony resistant kala-azar cured with amphotericin B].
    Chen SB; Yang CM; Zhang CJ
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Jun; 25(3):inside front page. PubMed ID: 18038767
    [No Abstract]   [Full Text] [Related]  

  • 47. Our experiences in visceral leishmaniasis therapy.
    Titone L; Scarlata F; Cascio A; Giordano S; Mancuso G
    J Chemother; 1989 Jul; 1(4 Suppl):960-1. PubMed ID: 16312722
    [No Abstract]   [Full Text] [Related]  

  • 48. Recurrences of tegumentary leishmaniasis.
    Weigle KA; Valderrama L; Santrich C; Saravia NG
    Lancet; 1985 Sep; 2(8454):557-8. PubMed ID: 2863579
    [No Abstract]   [Full Text] [Related]  

  • 49. Modifications of leucocyte function in visceral leishmaniasis.
    Lazzarin A; Esposito R; Almaviva M
    Boll Ist Sieroter Milan; 1981 Jul; 60(3):222-4. PubMed ID: 7326097
    [No Abstract]   [Full Text] [Related]  

  • 50. Post-kala-azar dermal leishmaniasis with visceral leishmaniasis: a rare presentation.
    Rijal A; Agrawal S; Agarwalla A; Agrawal A; Rijal S
    Int J Dermatol; 2005 Jun; 44(6):494-6. PubMed ID: 15941439
    [No Abstract]   [Full Text] [Related]  

  • 51. [Description of a case of visceral leishmaniasis. Epidemiologic, diagnostic and therapeutic considerations].
    Andreoli A; Cambiè M; Manzoni D; Bonora G; Gargantini G; Giaracuni G; Perletti L
    Minerva Pediatr; 1985 Jun; 37(11-12):479-84. PubMed ID: 4069094
    [No Abstract]   [Full Text] [Related]  

  • 52. [Treatment of cutaneous leishmaniasis with glucantime. Apropos of 9 cases].
    Ramos García AN; Pérez Avila J; Pérez Ramos E; Díaz Hernández A; Ruiz Pérez A
    Rev Cubana Med Trop; 1984; 36(2):151-9. PubMed ID: 6399595
    [No Abstract]   [Full Text] [Related]  

  • 53. Relative insensitivity of a Kenyan strain of Leishmania donovani to pentavalent antimony therapy in hamsters.
    Hanson WL; Waits VB; Hendricks LD; Hockmeyer WT; Davidson DE; Chapman WL
    J Parasitol; 1983 Apr; 69(2):446-7. PubMed ID: 6854484
    [No Abstract]   [Full Text] [Related]  

  • 54. Acute phase proteins and plasma lipoproteins during antimony treatment in infantile visceral leishmaniasis.
    Kallel R; Bekaert ED; Dubois DY; Alcindor LG; Ayrault-Jarrier M; Mebazza A
    Clin Physiol Biochem; 1993; 10(1):8-12. PubMed ID: 8339522
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Toxicity and efficacy of the antileishmanial drug meglumine antimoniate in the owl monkey (Aotus trivirgatus).
    Chapman WL; Hanson WL; Hendricks LD
    J Parasitol; 1983 Dec; 69(6):1176-7. PubMed ID: 6674468
    [No Abstract]   [Full Text] [Related]  

  • 56. Post-kala-azar dermal leishmaniasis.
    Baghestani S; Handjani F; Sodeifi M; Kumar PV
    Eur J Dermatol; 1998 Jun; 8(4):277-9. PubMed ID: 9649686
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [N-methyl glucamine antimoniate or Glucantime].
    Rapp C; Simon F; Dordain ML
    Med Trop (Mars); 2000; 60(4):342-3. PubMed ID: 11436584
    [No Abstract]   [Full Text] [Related]  

  • 58. Side effects of treatment with antimony salts.
    Malta R; Affronti M; Di Rosa S; Vassallo L; Renda M; Trifirò G; Rubino ME; Rini GB
    J Chemother; 1989 Jul; 1(4 Suppl):628-9. PubMed ID: 16312564
    [No Abstract]   [Full Text] [Related]  

  • 59. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate.
    Chulay JD; Fleckenstein L; Smith DH
    Trans R Soc Trop Med Hyg; 1988; 82(1):69-72. PubMed ID: 2845611
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ketoconazole in antimonial unresponsive cases of Kala-azar.
    Jha TK; Singh NK; Jha S
    J Assoc Physicians India; 1995 May; 43(5):347. PubMed ID: 9081966
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.